Request Your Free Infographic Now:

"Reference Materials for the Development of Assays for the Detection of Measurable Residual Disease in Acute Myeloid Leukemia"

The detection of minimal residual disease (MRD) in acute myeloid leukemia (AML) can present a challenge because it can require detecting just a few malignant cells within thousands -- if not millions -- of normal cells.

One of the major challenges associated with the development and validation of assays for MRD in AML is the absence of cell-based reference materials that feature diverse mutations that may be encountered clinically. To begin to address the need for standards, LGC SeraCare developed full-process cell-based reference materials that contain several mutations and formulated them at concentrations down to one in 100,000 in a background of normal leukocytes.

This scientific poster from LGC SeraCare describes the generation and validation of cell-based and ccfDNA-based reference materials for the development and validation of assays for the detection of MRD in AML.

Offered Free by: LGC SeraCare Life Sciences
See All Resources from: LGC SeraCare Life Sciences